A PHASE 2B, MULTICENTRE, MULTINATIONAL, PLACEBO-CONTROLLED, DOUBLE-BLIND, DOSE-FINDING STUDY IN ADULT PATIENTS WITH TYPE I, III OR IV OSTEOGENESIS IMPERFECTA TREATED WITH BPS804
- Registry ID
- MBPS205
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- MEREO BIOPHARMA 3 LIMITED
- Start date
- 2018-06-15
- Last update
- 2017-04-13
Conditions
Related clinical trials
- A PHASE 2, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSERANGING STUDY TO EVALUATE THE SAFETY AND EFFICACY OF AGA2115 IN ADULTS WITH TYPE
I, III, OR IV OSTEOGENESIS IMPERFECTA (OI)
- A PHASE 3, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO EVALUATE THE
EFFICACY AND SAFETY OF ROMOSOZUMAB COMPARED WITH BISPHOSPHONATES IN
CHILDREN AND ADOLESCENTS WITH OSTEOGENESIS IMPERFECTA
- AN OPEN-LABEL, RANDOMIZED, ACTIVE-CONTROLLED, PHASE 3 STUDY OF
SETRUSUMAB COMPARED WITH BISPHOSPHONATES IN PEDIATRIC SUBJECTS WITH
OSTEOGENESIS IMPERFECTA TYPES I, III OR IV
- A PHASE 1B, SINGLE ASCENDING DOSE, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND ACTIVITY OF SAR439459 IN ADULTS WITH OSTEOGENESIS IMPERFECTA
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2/3 STUDY TO ASSESS THE EFFICACY AND SAFETY OF SETRUSUMAB IN SUBJECTS WITH OSTEOGENESIS IMPERFECTA (OI)
- "MULTICENTER, SINGLE-ARM OPEN-LABEL EXTENSION STUDY TO ASSESS LONG-TERM SAFETY AND EFFICACY OF CURRENT OR PRIOR TREATMENT WITH DENOSUMAB IN CHILDREN/YOUNG ADULTS WITH OSTEOGENESIS IMPERFECTA
View on source registry